ReviewColorectal cancer2025
Stratified/risk-based screening for colorectal cancer in the UK: an overview.
Review in Colorectal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Public and Healthcare Professional Attitudes Towards Risk-Stratified Bowel Screening: A Qualitative Study Using an Info-Comic Book.Health expectations : an international journal of public participation in health care and health policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While colorectal cancer screening is well-established in the UK, at present, it uses a 'one-size fits-all' approach - that is, individual risk is not considered when determining screening regimens (except for some specific conditions such as Lynch syndrome). Stratified screening offers the prospect of directing more intensive screening toward those at higher risk - with a corresponding reduction of screening intensity among lower-risk individuals. Two key opportunities for stratifying colorectal cancer screening are (1) making better use of an individual's quantitative fecal hemoglobin result rather than the current approach of deeming tests to be positive over an arbitrary threshold and (2) gathering information on lifestyle, family history, genetics and other factors to establish risk of colorectal cancer - and using this information to tailor screening regimens. While there is encouraging evidence from modeling studies demonstrating reduced colonoscopy requirements and increased positive prediction of colorectal cancer when incorporating risk assessments within screening, we need 'real world' evidence on stratified screening to establish whether it is effective, improves screening outcomes and is acceptable to the public. We also need to know the impact these changes would have on existing screening programs, and how programs might adapt their organizational and IT processes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.